How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2016 Clinical Trials

82. A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: ORMD-0801 (qd) Drug: ORMD-0801 (bid) Drug: ORMD-0801 (tid) Other: Placebo Phase 2 Detailed Description: Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized (...) A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

83. Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

in HbA1c Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal; Change from baseline in body weight; Change from baseline in SBP for all patients. To evaluate the safety of sotagliflozin doses 1 and 2 versus placebo. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sotagliflozin (SAR439954) Drug: Placebo Phase 3 Detailed Description: Up to 34 weeks, including a Screening Period consisting of a Screening Phase of up to 2 weeks and a 2-week (...) Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2016 Clinical Trials

84. A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

. ClinicalTrials.gov Identifier: NCT02933853 Recruitment Status : Completed First Posted : October 14, 2016 Last Update Posted : January 8, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 (...) A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2016 Clinical Trials

85. Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

: NCT02906930 Recruitment Status : Completed First Posted : September 20, 2016 Last Update Posted : October 10, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. Condition or disease Intervention/treatment (...) Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2016 Clinical Trials

86. Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

in hemoglobin A1C (HbA1c) compared with placebo as assessed by change from baseline to Week 16 [Phase A (double-blind period)]. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Omarigliptin Drug: Placebo Biological: Insulin Phase 4 Detailed Description: After a screening period of up to 2 weeks followed by a pretreatment period of 2 or 10 weeks, each participant will be receiving assigned double-blind treatment (omarigliptin 25 mg or placebo once weekly) for approximately 16 (...) Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

87. Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

: March 7, 2018 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes. Condition or disease Intervention/treatment Diabetes Mellitus, Type 2, Cancer Drug: Pioglitazone Detailed Description: The study enroll a large population (...) Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus. Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

88. A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

with metformin plus placebo in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Ipragliflozin L-proline Drug: Metformin Drug: Placebo Phase 3 Detailed Description: This is a phase 3, double-blind, randomized study to assess the efficacy and safety of ipragliflozin in combination with metformin compared to metformin plus placebo in subjects in Russia with type 2 diabetes mellitus who have (...) A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2016 Clinical Trials

89. A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: This study will evaluate a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014 and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability (...) will be documented. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: LY900014 Drug: Insulin Lispro Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 28 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Basic Science Official Title: Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients

2016 Clinical Trials

90. Type 2 Diabetes Mellitus in Children

Type 2 Diabetes Mellitus in Children Type 2 Diabetes Mellitus in Children Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 2 (...) Diabetes Mellitus in Children Type 2 Diabetes Mellitus in Children Aka: Type 2 Diabetes Mellitus in Children , Pediatric Type II Diabetes Mellitus , Non-Insulin Dependent Diabetes in Children From Related Chapters II. Epidemiology One in 3 new cases of childhood in U.S. are type 2 III. Risk Factors (BMI) >85th percentile for age and gender or Weight for Height >85th percentile for age and gender or for height >120th percentile for age and gender of Type 2 Diabetes in first or second degree relative

2018 FP Notebook

91. Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 1 Diabetes Mellitus Type 1 (...) eyesight A blood test can show if you have diabetes. If you do, you will need to take for the rest of your life. NIH: National Institute of Diabetes and Digestive and Kidney Diseases Definition (NCI) A chronic condition characterized by minimal or absent production of insulin by the pancreas.(NICHD) Definition (MSH) A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS

2018 FP Notebook

92. Diabetes Mellitus Control in Hospital

Diabetes Mellitus Control in Hospital Diabetes Mellitus Control in Hospital Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diabetes (...) Mellitus Control in Hospital Diabetes Mellitus Control in Hospital Aka: Diabetes Mellitus Control in Hospital , Inpatient Diabetes Control , Glycemic Control in Hospitalized Patients , Inpatient Glucose Management , Emergency Department Hyperglycemia Management From Related Chapters II. Complications: Uncontrolled Blood Glucose Decreased survival Increased cardiac or Worse outcomes following cerebovascular accident Increased mortality following acute Increased nosocmial and s Delayed Prolonged

2018 FP Notebook

93. Diabetes Mellitus Glucose Management

Diabetes Mellitus Glucose Management Diabetes Mellitus Glucose Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diabetes (...) Mellitus Glucose Management Diabetes Mellitus Glucose Management Aka: Diabetes Mellitus Glucose Management , Blood Glucose Monitoring Goals , Blood Glucose Monitoring Schedule , Blood Glucose Monitoring , Blood Sugar Monitoring From Related Chapters II. History: Diabetes Mellitus Pharmacology 1922: Crude Extracts by Banting and Best 1940: developed 1950: s developed 1960: s off market 1970: s III. Protocol: Blood Glucose Monitoring Goals Target (>50% of readings in range) Children under age 6 Before

2018 FP Notebook

94. Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Type 2 Diabetes Mellitus Type 2 (...) Diabetes Mellitus Aka: Type 2 Diabetes Mellitus , Type II Diabetes Mellitus , Non-Insulin Dependent Diabetes Mellitus , NIDDM , Type II Diabetes From Related Chapters II. Epidemiology Represents 90% of all Typically occurs over age 40 years in obese patients Type II Diabetes Mellitus is rapidly increasing in the United States : 22 Million in 2014 (was 5.5 Million in 1980) More than 8 Million are estimated to be undiagnosed (27%) Over 29 Million people with Type II Diabetes represents over 9% of the U.S

2018 FP Notebook

95. Gastrointestinal Manifestations of Diabetes Mellitus

Gastrointestinal Manifestations of Diabetes Mellitus Gastrointestinal Manifestations of Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse (...) Cancer Administration 4 Gastrointestinal Manifestations of Diabetes Mellitus Gastrointestinal Manifestations of Diabetes Mellitus Aka: Gastrointestinal Manifestations of Diabetes Mellitus , Diabetes Related Gastrointestinal Conditions II. Associated Conditions: Esophagus, Stomach and Bowel Increased with longer standing (Type I or Type II) Esophageal Reflux Mechanism: , decreased lower esophageal sphincter tone, prolonged transit time ( ) Increased association with (5-10 fold increased risk

2018 FP Notebook

96. Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

baseline to week 26 in patients with type 2 diabetes mellitus. Secondary Objective: To compare overall efficacy and safety of LixiLan to insulin glargine over 26 weeks in patients with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010) Drug: Insulin glargine U100 (HOE901) Drug: Metformin Phase 3 Detailed Description: The maximum study duration per patient will be approximately 41 weeks: an up to 14 (...) Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

97. Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

, tolerability and immunogenicity data for the albiglutide liquid drug product. This extension study will comprise 2 study periods: treatment (26 weeks) and post-treatment follow-up (8 weeks). A maximum of 300 subjects will be eligible to take part in this extension study. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Albiglutide Device: Auto-injector Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual (...) Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2016 Clinical Trials

98. A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/liraglutide Drug: insulin glargine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical (...) A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2016 Clinical Trials

99. A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 1 Drug: NNC0143-0406 Drug: Insulin Aspart Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 47 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official (...) A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2016 Clinical Trials

100. Use of Stem Cells in Diabetes Mellitus Type 1

-Adwan, University of Jordan Study Details Study Description Go to Brief Summary: Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus Type 1 Biological: Adipose mesenchymal cells with bone marrow mononuclear cells Phase 1 Detailed Description: Adipose derived mesenchymal stem cells (ASCs) are to be collected from blood group O donor, cells will be passaged (...) Patients with Type 1 Diabetes Mellitus. Age from 18 years to 35 years either gender. Duration of disease: not exceeding 3 years unless C-peptide is not less than 0.5 ng/ml C-Peptide at inclusion base line should not be less than 0.5 ng/ml No clinical evidence of renal, retinal, vascular or skin complications Body Mass Index not exceeding 30 Any HbA1c At least one positive antibody either anti-Glutamic Acid Decarboxylase-65 or Insulinoma-Associated-2 Autoantibodies (anti-1A2) Informed Consent by patient

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>